Hemostemix Inc. (CVE:HEM – Get Free Report) rose 27.8% on Saturday . The stock traded as high as C$0.12 and last traded at C$0.12. Approximately 335,071 shares were traded during trading, a decline of 31% from the average daily volume of 486,759 shares. The stock had previously closed at C$0.09.
Hemostemix Trading Up 27.8%
The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The company has a fifty day simple moving average of C$0.10 and a two-hundred day simple moving average of C$0.14. The company has a market capitalization of C$16.76 million, a P/E ratio of -3.35 and a beta of 0.20.
Insider Transactions at Hemostemix
In other Hemostemix news, Director Peter Alan Lacey acquired 200,000 shares of the company’s stock in a transaction dated Thursday, March 6th. The shares were acquired at an average cost of C$0.15 per share, for a total transaction of C$30,000.00. 10.43% of the stock is currently owned by corporate insiders.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- e.l.f. Gets Back on the Shelf! It’s Not Too Late to Buy In!
- Ride Out The Recession With These Dividend Kings
- Near 52-Week Lows, These 3 Mid-Cap Stocks Are Worth a Look
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
